

Indikation	Protokoll	NCT #	Prüfsubstanz	Studientitel
NSCLC	MS 200095-0022	NCT02864992	Tepotinib	A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)
NSCLC	CACZ885T2301	NCT03447769	Canakinumab	A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
NSCLC	CACZ885T2301A	--	--	Biomarker bei Patienten passend für CACZ885T2301 vor + nach OP
NSCLC	BO29554	NCT03178552	Entrectinib	A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (B-FAST: BLOOD-FIRST ASSAY SCREENING TRIAL)
NSCLC	GO40241	NCT03456063	Atezolizumab	A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NSCLC	205801	NCT03739710	GSK3359609 (ICOS Agonist)	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
NSCLC	D4194C00006	NCT03693300	Durvalumab	A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
Plattenepithelkarzinom	Uni-Koeln-3254	NCT03827850	Erdafitinib	A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced squamous NSCLC (sqNSCLC) harboring FGFR genetic alterations after relapse of standard therapy
NSCLC	AIO-TRK-0117	--	Nintedanib + Nivolumab	Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology – An AIO phase Ib trial
NSCLC	MS200647_0037	NCT03631706	M7824	A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer
NSCLC	Brigatinib 3001	NCT03596866	Brigatinib	A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
NSCLC	M14-239	NCT03539536	Telisotuzumab vedotin	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
SCLC	D933QC00001	NCT03703297	Durvalumab, Tremelimumab, Placebo	A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
SCLC	C-II-011	NCT03227016	Veliparib	Phase/II Study in Patients with Small Cell Lung Cancer (SCLC) of Veliparib in Combination with Topotecan, 2nd line
Cachexie	ANAM-17-21	NCT03743064	Anamorelin HCL	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANAMORELIN HCL FOR THE TREATMENT OF MALIGNANCY ASSOCIATED WEIGHT LOSS AND ANOREXIA IN ADULT PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (NSCLC)
NSCLC	AIO-TRK-0315	NCT02622581	nur Dokumentation	Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients
NSCLC	ML39885	NCT03559647	nur Dokumentation	THE EFFECTIVENESS OF ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS WITH LOCALLY-ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER PRIOR CHEMOTHERAPY